Michael Hansbury - Concepedia

Author

Michael Hansbury

Also Known As

Hansbury, M., Hansbury, Michael J., M. Hansbury, M.J. Hansbury, Michael Hansbury, Michael J Hansbury, Michael J. Hansbury

Publications

2.3K

Citations

H-Index

Concepts

All Affiliations

Incyte (United States)New Frontier GlaxoSmithKline (United States)Rowan University GlaxoSmithKline (Italy)

About

Michael Hansbury is an author at Incyte (United States) specializing in medicine, pharmacology, and natural sciences.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	734
2	Natural Sciences	5	5	518
3	Biochemistry	4	4	330
4	Cell Biology	4	4	255
5	Biomolecular Engineering	1	1	50

Michael Hansbury

Publications

2.2K

Citations

H-Index

Page 1

	Year	Citations
Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity Xiangdong Liu, Niu Shin, Holly K. Koblish, Blood	2010	552
INCB24360 (Epacadostat), a Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitor for Immuno-oncology Eddy W. Yue, Richard Sparks, Padmaja Polam, ACS Medicinal Chemistry Letters	2017	290
Hydroxyamidine Inhibitors of Indoleamine-2,3-dioxygenase Potently Suppress Systemic Tryptophan Catabolism and the Growth of IDO-Expressing Tumors Holly K. Koblish, Michael Hansbury, Kevin Bowman, Molecular Cancer Therapeutics	2010	243
Discovery of Potent Competitive Inhibitors of Indoleamine 2,3-Dioxygenase with in Vivo Pharmacodynamic Activity and Efficacy in a Mouse Melanoma Model Eddy W. Yue, Brent Douty, Brian Wayland, Journal of Medicinal Chemistry PharmacotherapyVivo Pharmacodynamic ActivityPharmaceutical ChemistryTumor BiologyMedicinal Chemistry	2009	216
4-Aryl-1,2,3-triazole: A Novel Template for a Reversible Methionine Aminopeptidase 2 Inhibitor, Optimized To Inhibit Angiogenesis in Vivo Lara S. Kallander, Qing Lü, Wenfang Chen, Journal of Medicinal Chemistry Mouse Matrigel ModelEndothelial Cell GrowthPharmacotherapyChemical BiologyPharmaceutical Chemistry	2005	188
INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models Phillip C.C. Liu, Holly K. Koblish, Liangxing Wu, PLoS ONE Fgfr AlterationsMedicinePharmacologySelective InhibitorPathology	2020	158
Selective Inhibition of ADAM Metalloproteases as a Novel Approach for Modulating ErbB Pathways in Cancer Jordan S. Fridman, Eian Caulder, Michael Hansbury, Clinical Cancer Research	2007	143
Constitutive expression of angiopoietin-1 and -2 and modulation of their expression by inflammatory cytokines in rheumatoid arthritis synovial fibroblasts. Boyd B. Scott, Paola Zaratin, Antonio Colombo, PubMed	2002	84
dUTPase and uracil-DNA glycosylase are central modulators of antifolate toxicity in Saccharomyces cerevisiae. Beverly A Tinkelenberg, Michael Hansbury, Robert D. Ladner PubMed Dutpase ActivityUracil-dna GlycosylaseMolecular BiologyDrug ResistanceYeast	2002	50
IgE secretion is attenuated by an inhibitor of proteolytic processing of CD23 (FcεRII) Gary Christie, A. D. Barton, Brian Bolognese, European Journal of Immunology	1997	50

Page 1